|
US4405616A
(en)
*
|
1975-06-19 |
1983-09-20 |
Nelson Research & Development Company |
Penetration enhancers for transdermal drug delivery of systemic agents
|
|
US4316893A
(en)
*
|
1975-06-19 |
1982-02-23 |
Nelson Research & Development Co. |
Vehicle composition containing 1-substituted azacycloalkan-2-ones
|
|
US3989816A
(en)
*
|
1975-06-19 |
1976-11-02 |
Nelson Research & Development Company |
Vehicle composition containing 1-substituted azacycloheptan-2-ones
|
|
US4557934A
(en)
*
|
1983-06-21 |
1985-12-10 |
The Procter & Gamble Company |
Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
|
|
US4524008A
(en)
|
1983-12-16 |
1985-06-18 |
E. I. Du Pont De Nemours And Company |
Controlled initiation chromium dioxide synthesis
|
|
US4568343A
(en)
*
|
1984-10-09 |
1986-02-04 |
Alza Corporation |
Skin permeation enhancer compositions
|
|
US5023252A
(en)
*
|
1985-12-04 |
1991-06-11 |
Conrex Pharmaceutical Corporation |
Transdermal and trans-membrane delivery of drugs
|
|
US4783450A
(en)
|
1987-04-13 |
1988-11-08 |
Warner-Lambert Company |
Use of commercial lecithin as skin penetration enhancer
|
|
US5001139A
(en)
*
|
1987-06-12 |
1991-03-19 |
American Cyanamid Company |
Enchancers for the transdermal flux of nivadipine
|
|
US4992445A
(en)
*
|
1987-06-12 |
1991-02-12 |
American Cyanamid Co. |
Transdermal delivery of pharmaceuticals
|
|
DE3802996A1
(de)
*
|
1988-02-02 |
1989-08-10 |
Cassella Ag |
Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen
|
|
US5424399A
(en)
*
|
1988-06-28 |
1995-06-13 |
The Children's Medical Center Corporation |
Human CR3α/β heterodimers
|
|
US5149780A
(en)
*
|
1988-10-03 |
1992-09-22 |
The Scripps Research Institute |
Peptides and antibodies that inhibit integrin-ligand binding
|
|
JPH06500555A
(ja)
*
|
1990-08-27 |
1994-01-20 |
カイロン コーポレイション |
病気の処置のためのペプチドの薬物
|
|
US5288854A
(en)
*
|
1990-11-28 |
1994-02-22 |
Center For Blood Research, Inc. |
Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
|
|
AU2777092A
(en)
*
|
1991-10-04 |
1993-05-03 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Treatment of ocular inflammation by blockage of cell adhesion molecules
|
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
US6162432A
(en)
*
|
1991-10-07 |
2000-12-19 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
WO1993017047A1
(en)
*
|
1992-02-28 |
1993-09-02 |
Board Of Regents, The University Of Texas System |
Compositions and methods for the treatment of thermal injury
|
|
US5298492A
(en)
*
|
1992-08-04 |
1994-03-29 |
Schering Corporation |
Diamino acid derivatives as antihypertensives
|
|
CA2140933A1
(en)
*
|
1992-08-21 |
1994-02-22 |
Paula M. Jardieu |
Method for treating an lfa-1 mediated disorder
|
|
US5397791A
(en)
*
|
1993-08-09 |
1995-03-14 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
DE59409322D1
(de)
*
|
1993-12-03 |
2000-06-08 |
Hoffmann La Roche |
Essigsäurederivate als Arzneimittel
|
|
US5470953A
(en)
*
|
1993-12-23 |
1995-11-28 |
Icos Corporation |
Human β2 integrin α subunit
|
|
US6228383B1
(en)
|
1994-03-03 |
2001-05-08 |
Gs Development Ab |
Use of fatty acid esters as bioadhesive substances
|
|
EP0762886A4
(en)
|
1994-04-19 |
1999-03-31 |
Univ Kansas |
ICAM-1 / LFA-1 SHORT CHAIN PEPTIDES AND METHODS FOR USE THEREOF
|
|
US5585359A
(en)
*
|
1994-09-29 |
1996-12-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
ATE170179T1
(de)
*
|
1994-11-02 |
1998-09-15 |
Merck Patent Gmbh |
Adhäsionsrezeptor-antagonisten
|
|
US5747035A
(en)
*
|
1995-04-14 |
1998-05-05 |
Genentech, Inc. |
Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
|
|
WO1997005185A2
(en)
|
1995-07-28 |
1997-02-13 |
Focal, Inc. |
Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents
|
|
PT944619E
(pt)
*
|
1996-11-27 |
2007-01-31 |
Bristol Myers Squibb Pharma Co |
Novos antagonistas dos receptores da integrina
|
|
ES2306482T3
(es)
|
1997-08-28 |
2008-11-01 |
Novartis Ag |
Antagonistas de antigeno-1 funcion con funcion de linfocito.
|
|
US6541606B2
(en)
*
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
|
CA2325986A1
(en)
|
1998-03-27 |
1999-10-07 |
Genentech, Inc. |
Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
|
|
US6331640B1
(en)
|
1998-10-13 |
2001-12-18 |
Hoffmann-La Roche Inc. |
Diaminopropionic acid derivatives
|
|
US6670321B1
(en)
*
|
1998-12-30 |
2003-12-30 |
The Children's Medical Center Corporation |
Prevention and treatment for retinal ischemia and edema
|
|
NZ511219A
(en)
*
|
1999-01-05 |
2003-05-30 |
Univ Southern Australia |
Novel agents and methods for treatment and diagnosis of ocular disorders
|
|
EP1028114A1
(en)
*
|
1999-02-13 |
2000-08-16 |
Aventis Pharma Deutschland GmbH |
Novel guanidine derivatives as inhibitors of cell adhesion
|
|
US6294522B1
(en)
*
|
1999-12-03 |
2001-09-25 |
Cv Therapeutics, Inc. |
N6 heterocyclic 8-modified adenosine derivatives
|
|
US6605597B1
(en)
*
|
1999-12-03 |
2003-08-12 |
Cv Therapeutics, Inc. |
Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
|
|
EP1237575B1
(en)
*
|
1999-12-14 |
2008-08-06 |
Genentech, Inc. |
Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis
|
|
DE60110396T2
(de)
|
2000-01-14 |
2006-01-19 |
Larson, Richard S., Albuquerque |
Peptidische inhibitoren der lfa-1/icam-1 interaktion
|
|
US6515124B2
(en)
|
2000-02-09 |
2003-02-04 |
Hoffman-La Roche Inc. |
Dehydroamino acids
|
|
EP1296943A1
(fr)
*
|
2000-05-05 |
2003-04-02 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) |
Derives d'aminoacides et leur application a titre de medicaments
|
|
AU2001268718B2
(en)
*
|
2000-06-29 |
2006-01-05 |
Abbott Laboratories |
Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
|
|
AR030817A1
(es)
*
|
2000-10-02 |
2003-09-03 |
Novartis Ag |
Derivados de diazacicloalcanodiona
|
|
US6653478B2
(en)
*
|
2000-10-27 |
2003-11-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
|
|
GB0028367D0
(en)
*
|
2000-11-21 |
2001-01-03 |
Celltech Chiroscience Ltd |
Chemical compounds
|
|
IL155683A0
(en)
*
|
2000-11-28 |
2003-11-23 |
Genentech Inc |
Lfa-1 antagonist compounds
|
|
DE60216830T2
(de)
*
|
2001-02-06 |
2007-06-14 |
Pfizer Products Inc., Groton |
Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
|
|
US20030044406A1
(en)
*
|
2001-03-02 |
2003-03-06 |
Christine Dingivan |
Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
|
|
US6391290B1
(en)
|
2001-03-21 |
2002-05-21 |
Schering-Plough Healthcare Products, Inc. |
Skin care compositions
|
|
US6872382B1
(en)
*
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
JP4583751B2
(ja)
*
|
2001-06-06 |
2010-11-17 |
アベンティス・フアーマ・リミテッド |
炎症性疾患の治療に使用するための置換されたテトラヒドロイソキノリン
|
|
AU2002320352A1
(en)
*
|
2001-07-24 |
2003-02-17 |
Biogen Idec Ma Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
|
RU26988U1
(ru)
|
2002-05-06 |
2003-01-10 |
Закрытое акционерное общество "ДУКС-ЛИЗИНГ" |
Кондуктор для сверления отверстий
|
|
WO2003103587A2
(en)
*
|
2002-06-06 |
2003-12-18 |
Dana-Farber Cancer Institute |
Compounds or agents that inhibit and induce the formation of focal microvessel dilatations
|
|
US7785578B2
(en)
*
|
2002-10-11 |
2010-08-31 |
Aciont, Inc. |
Non-invasive ocular drug delivery
|
|
AU2004287875B2
(en)
*
|
2003-11-05 |
2011-06-02 |
Bausch + Lomb Ireland Limited |
Modulators of cellular adhesion
|
|
SI1682537T1
(sl)
*
|
2003-11-05 |
2012-08-31 |
Sarcode Bioscience Inc |
Modulatorji celularne adhezije
|
|
WO2005065668A2
(en)
*
|
2003-12-29 |
2005-07-21 |
Qlt Usa, Inc. |
Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
|
|
EP1756163A2
(en)
*
|
2004-06-09 |
2007-02-28 |
Genentech, Inc. |
Method of treating granuloma annulare or sarcoid
|
|
KR20070034129A
(ko)
*
|
2004-07-22 |
2007-03-27 |
와이어쓰 |
신경계 질환 및 장애의 치료 방법
|
|
SI1881823T1
(sl)
*
|
2005-05-17 |
2015-04-30 |
Sarcode Bioscience Inc. |
Sestavki in postopki za zdravljenje bolezni oäśesa
|
|
CA2702984C
(en)
*
|
2007-10-19 |
2017-04-11 |
Sarcode Corporation |
Compositions and methods for treatment of diabetic retinopathy
|
|
EP2276508A4
(en)
*
|
2008-04-15 |
2011-12-28 |
Sarcode Bioscience Inc |
ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
|
|
WO2009139817A2
(en)
*
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
CN102065694A
(zh)
*
|
2008-04-15 |
2011-05-18 |
萨可德公司 |
用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
|
|
US8378105B2
(en)
*
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
EP2877465A4
(en)
*
|
2012-07-25 |
2016-05-11 |
Sarcode Bioscience Inc |
LFA-1 HEMMER AND POLYMORPH THEREOF
|